These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32442855)

  • 1. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications.
    Roytman M; Pisapia DJ; Liechty B; Lin E; Skafida M; Magge RS; Osborne JR; Pannullo SC; Knisely JPS; Ramakrishna R; Ivanidze J
    Clin Imaging; 2020 Oct; 66():18-22. PubMed ID: 32442855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
    Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
    J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma.
    Wang S; Yang W; Deng J; Zhang J; Ma F; Wang J
    J Neurooncol; 2013 Jul; 113(3):519-26. PubMed ID: 23657621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
    Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
    Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas.
    Ivanidze J; Roytman M; Lin E; Magge RS; Pisapia DJ; Liechty B; Karakatsanis N; Ramakrishna R; Knisely J; Schwartz TH; Osborne JR; Pannullo SC
    J Neuroimaging; 2019 Sep; 29(5):650-656. PubMed ID: 31107591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging.
    Bashir A; Broholm H; Clasen-Linde E; Vestergaard MB; Law I
    Clin Nucl Med; 2020 Jun; 45(6):e279-e280. PubMed ID: 32332303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor-positive granulomatous inflammation mimicking as meningioma on simultaneous PET/MRI.
    Taneja S; Jena A; Kaul S; Jha A; Sogani SK
    Clin Nucl Med; 2015 Jan; 40(1):e71-2. PubMed ID: 24662657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication.
    Dressen MS; Muthukrishnan A; Tragon TR; Lieberman FS; Mountz JM
    Clin Nucl Med; 2019 Jan; 44(1):e26-e27. PubMed ID: 30371576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas.
    Meewes C; Bohuslavizki KH; Krisch B; Held-Feindt J; Henze E; Clausen M
    J Nucl Med; 2001 Sep; 42(9):1338-45. PubMed ID: 11535722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of [
    Bashir A; Vestergaard MB; Binderup T; Broholm H; Marner L; Ziebell M; Fugleholm K; Mathiesen T; Kjær A; Law I
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2577-2588. PubMed ID: 32170347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
    Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
    Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas.
    Nathoo N; Ugokwe K; Chang AS; Li L; Ross J; Suh JH; Vogelbaum MA; Barnett GH
    J Neurooncol; 2007 Jan; 81(2):167-74. PubMed ID: 16850106
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
    Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
    Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
    Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions.
    Ensign SF; Agarwal M; Klanderman M; Badawy M; Halfdanarson TR; Johnson DR; Sonbol MB; Kendi AT
    Nucl Med Commun; 2023 Jul; 44(7):663-670. PubMed ID: 37158225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive differentiation of meningiomas from other brain tumours using combined 111Indium-octreotide/99mtechnetium-DTPA brain scintigraphy.
    Barth A; Haldemann AR; Reubi JC; Godoy N; Rösler H; Kinser JA; Seiler RW
    Acta Neurochir (Wien); 1996; 138(10):1179-85. PubMed ID: 8955437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.